In NRG-GY018/KEYNOTE-868, KEYTRUDA in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, ...

Merck's Keytruda now approved by European Commission for new gynecologic cancer indications, expanding its reach in the EU.

The European Commission (EC) has approved two new indications for Keytruda (pembrolizumab), Merck & Co’s anti-PD-1 therapy, ...

Merck (MRK) announced that the European Commission (EC) has approved two new indications for Keytruda, Merck’s anti-PD-1 therapy, in ...

Three absurdly cheap dividend stocks that are trading at modest multiples of their expected earnings today are Merck (NYSE: ...

To say this has been a big year for Summit Therapeutics (NASDAQ: SMMT) would be a huge understatement. The stock has risen ...

A 72-year-old cancer patient is voting to save the Affordable Care Act. A husband votes to save his wife's right to choose.

After the disastrous performance of 2022, the market has recovered better than expected and is on a growth trajectory.

Shortly after Bicara Therapeutics raised more than $360 million in an IPO, the cancer biotech and its former parent company ...

Lacy listed Keytruda, a cancer treatment, costs about R100 000 per cycle. “By costs, we mean not just treatment and care but ...

Yet, one analyst told Barron’s that “rarely in my 20 years as an analyst have I seen a company with so much potential.” He ...

Finshark, one of the Nordics' leading providers of online banking payments, real-time payouts, and financial insights, has taken a significant step forward in its mission to offer the most secure and ...